94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
MINI REVIEW article
Front. Med.
Sec. Hematology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1553936
This article is part of the Research Topic Immune Thrombocytopenia (ITP) - Diagnosis and Treatment - Volume II View all 5 articles
Immune thrombocytopenia in Adolescents and Young Adults
Provisionally accepted- University Children’s Hospital Basel, Basel, Switzerland
Previous guidelines for the treatment of immune thrombocytopenia (ITP) have traditionally focused on a dichotomy between pediatric and adult ITP. Adolescents and young adults (AYAs) do not neatly fit into either the pediatric or adult ITP group. A deeper understanding of ITP's natural history, risk factors for chronicity, and outcomes in AYAs is a crucial first step toward developing tailored treatment algorithms. Such data could form the basis for recommendations targeting this underrepresented yet clinically distinct population. Ultimately, age-adapted trials may improve longterm outcomes, reduce toxicity, and enhance HRQoL for AYAs with ITP. The AYAS collaboration-drawing on data from the Pediatric and Adult Registry on Chronic ITP (PARC-ITP), the Cytopénies Auto-immunes Registre Midi-Pyrénéen-France (CARMEN-France) adult registry in Toulouse, and the National Prospective Cohort Follow-Up for Children with Severe Autoimmune Cytopenia (OBS'CEREVANCE) pediatric cohort in Bordeaux, France-aims to address the information gap in AYAs with ITP. To date, four analyses have been undertaken (using data from 2004 to 2021), each addressing the major clinical aspects of ITP in patients aged 12-25 years: (1) newly diagnosed ITP, (2) chronic disease, (3) refractory courses, and (4) secondary (sITP) forms.
Keywords: ITp, Ayas, Secondary ITP, Chronic ITP, Sustained remission
Received: 31 Dec 2024; Accepted: 21 Feb 2025.
Copyright: © 2025 Schifferli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Alexandra Schifferli, University Children’s Hospital Basel, Basel, Switzerland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.